Insensitivity to T790M mutation? A pooled analysis of outcomes following osimertinib for the treatment of NSCLC patients harboring uncommon epidermal growth factor receptor mutation

Insensitivity to T790M mutation? A pooled analysis of outcomes following osimertinib for the treatment of NSCLC patients harboring uncommon epidermal growth factor receptor mutation

Background: In this pooled analysis, the aim was to investigate the clinicopathological characteristics of patients with uncommon epidermal growth factor receptor (EGFR) (ucm-EGFRms) along with their treatment responses and survival following osimertinib treatment.Methods: Univariate chi-square anal...

Full description

Bibliographic Details
Main Authors: Shanliang Hu, Congjie Wang, Chunsheng Wang, Kewei Zhao, Zhen Wang, Wei Dong
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Pharmacology
Subjects:
osimertinib
uncommon
EGFR
Efficacy
Prognosis
NSCLC6
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.986962/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.986962/full

Similar Items